Society for Research on Nicotine and Tobacco

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Friday, March 3, 2023
Smoker, FDA, Nicotine, University of California, San Francisco Fetal Treatment Center, Harvard Medical School, CST, Smoking, Research, Society for Research on Nicotine and Tobacco, Annual general meeting, Society, Massachusetts General Hospital, Pharmaceutical industry, Birth control, Medicine, Tobacco

The presentation will be given by ORCA-2 Principal Investigator, Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital.

Key Points: 
  • The presentation will be given by ORCA-2 Principal Investigator, Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital.
  • Subjects who received either 6 or 12-weeks of cytisinicline treatment experienced consistently higher rates of abstinence.
  • The Company continues to expect topline data results for both trials to be announced in the second quarter of 2023.
  • To learn more about SRNT or the SRNT Annual Meeting, please visit www.srnt.org .

Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022
Degenerative disease, Research, Nicotine, Risk, GLOBE, Health, Private Securities Litigation Reform Act, COVID-19, Nature, Annual general meeting, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Society, Security (finance), Brain, NASDAQ, Society for Research on Nicotine and Tobacco, Smoking, EDT, Moyamoya disease, Food, Goal, Reward, Tobacco smoking, Death, U.S. Securities and Exchange Commission, Lung cancer, Tobacco, Pharmaceutical industry, MD, Tobacco

SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a presentation on cytisinicline will be held during the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, being held in Baltimore, MD, March 15-18, 2022.

Key Points: 
  • SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a presentation on cytisinicline will be held during the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, being held in Baltimore, MD, March 15-18, 2022.
  • An overview of the cytisinicline development program will be included in the Promising New Smoking Cessation Pharmacotherapies Symposium, to be held on Wednesday, March 16, at 3:00 p.m. EDT.
  • For additional information on the SRNT Annual Meeting, including registration details, please visit www.srnt.org .
  • Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.

E-Cig Clinical Trial Results Shared at the Society for Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022
Research, Nicotine, Technology, GLOBE, JUUL, Toxicology, Public health, FDA, Tobacco Products Scientific Advisory Committee, Stick, ENDS, Marketing, Compliance, LLC, EST, Society, Adult, Society for Research on Nicotine and Tobacco, UL, Food, Company, Regulatory science, American Board of Commissioners for Foreign Missions, Policy, Smoker, Regulation of tobacco by the U.S. Food and Drug Administration, Tobacco, Altria, Tobacco

These results support BIDI Stick as a potentially satisfying alternative to cigarette smoking for adult smokers.

Key Points: 
  • These results support BIDI Stick as a potentially satisfying alternative to cigarette smoking for adult smokers.
  • The 28th Annual SRNT Meeting will be held at the Hilton Baltimore Inner Harbor hotel in Baltimore from March 15-18, 2022.
  • SRNT is the professional society for those working on tobacco and nicotine scientific questions in pre-clinical, clinical, public health, epidemiological, and policy and regulatory research domains.
  • For more information on this press release contact Angel Abcede, press manager for QRX Digital, at [email protected].

Canadian Vaping Association: 100 experts in nicotine science and policy challenge the WHO to change its stance on vaping

Retrieved on: 
Thursday, October 21, 2021
Science, Death, Conference of the Parties, Benefit, Sustainable Development Goals, Nicotine, Society for Research on Nicotine and Tobacco, Policy, Society, Smokeless tobacco, Â, Leadership, Delegation, Conference, Smoking, Adult, Risk, CVA, Essay, Herbal cigarette, Smoker, Public health, Health, COP9, WHO, Research, FCTC, GLOBE, Legislation, Tobacco, Risk management

Often restrictions to vape products are justified as cautious policy, with health agencies citing uncertainty in vapings long term health consequences.

Key Points: 
  • Often restrictions to vape products are justified as cautious policy, with health agencies citing uncertainty in vapings long term health consequences.
  • We believe that it is time for global tobacco policy to draw on the full potential of tobacco harm reduction.
  • Many of the worlds most credible experts are speaking out at the highest levels to advocate that vaping remains accessible to adult smokers.
  • The experts and the science have been clear that if properly supported vaping could prevent the premature death of millions of people globally, said Darryl Tempest, Executive Director of the CVA.